TrxR
Thioredoxin Reductase
TrxR (Thioredoxin Reductase) is a selenium-containing pyridine nucleotide-disulphide oxidoreductase. There are three isoforms of mammalian TrxRs: TrxR1 (TXRND1), TrxR2 (TXNRD2) and TrxR3 (TGR). TrxRs catalyze the NADPH-dependent reduction of the redox protein thioredoxin (Trx). TrxR is important in regulating the intracellular redox environment, cell growth and transformation, as well as the recycling of ascorbate from its oxidized form. Trx/TrxR system is associated with the cancers, metabolic syndrome, insulin resistance, and type 2 diabetes, as well as in hypertension and atherosclerosis[1][2].
References:
- [1]. Mustacich D, et al. Thioredoxin reductase. Biochem J. 2000 Feb 15;346 Pt 1(Pt 1):1-8. [Content Brief]
- [2]. Tinkov AA, et al. The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker? Cell Mol Life Sci. 2018 May;75(9):1567-1586. [Content Brief]
TrxR Isoform Specific Products
All Product Categories
-
TrxR Related Products (48)
Related Products (48)
-
Antibodies (6)
-
TrxR Isoform Comparison
-
Fa-Au
0 ImagesCat. No.: HY-183554Fa-Au is a TrxR inhibitor. Fa-Au downregulates GPX4, induces oxidative stress, mitochondria-associated ferroptosis (ferroptosis) and immunogenic cell death. Fa-Au induces ROS production in hepatoma cells. Fa-Au remodels the tumor immune microenvironment via M1 macrophage polarization, dendritic cell maturation, CD8+ T cell activation and reduction of regulatory T cells. Fa-Au induces an anti-tumor immune feedback loop through the IFNγ/STAT1/SLC7A11 axis. Fa-Au inhibits tumor growth. Fa-Au is applicable to hepatocellular carcinoma-related research.
-
TrxR-IN-9
0 ImagesCat. No.: HY-181825TrxR-IN-9 is a thioredoxin reductase (TrxR) inhibitor with an IC50 of 0.26 μM. TrxR-IN-9 disrupts cellular redox balance. TrxR-IN-9 induces S-phase cell cycle arrest, promotes apoptosis and exhibits antiproliferative activity across cancer cells. TrxR-IN-9 exerts effects via synergistic nitric oxide (NO) and reactive oxygen species (ROS) action. TrxR-IN-9 can be used for the research of breast cancer, gastric cancer, colorectal cancer, liver cancer.
-
BGC4
0 ImagesCat. No.: HY-172115BGC4 is a biphenyl-based gold(III) complex. BGC4 inhibits human recombinant thioredoxin reductase (TrxR) with an IC50 of 10.7 μM, exhibits cytotoxicity (IC50 for MDA-MB-231 is 5.4 μM), and induces apoptosis. BGC4 exhibits antitumor efficacy in mouse models.
-
As-CA11
0 ImagesCat. No.: HY-179712As-CA11 is a Thioredoxin reductase (TrxR) inhibitor with an IC50 of 18.7 nM. As-CA11 can induce cancer cells apoptosis and ROS production. As-CA11 can reduce the level of reduced Trx and increase the level of oxidized Trx. As-CA11 demonstrates anti-tumor activity in the 4T1 tumor-bearing mouse model.
-
TrxR1-IN-3
0 ImagesCat. No.: HY-184328CAS No.: 3028398-90-2TrxR1-IN-3 is a selective TrxR1 inhibitor with an IC50 of 1.19 μM. TrxR1-IN-3 increases intracellular reactive oxygen species (ROS) levels, induces endoplasmic reticulum (ER) stress, and activates Caspase-dependent Apoptosis. TrxR1-IN-3 exhibits anticancer activity against multiple breast cancer subtypes, including triple-negative breast cancer (TNBC). TrxR1-IN-3 can be used in breast cancer-related research.
-
TrxR1-IN-B19
0 ImagesCat. No.: HY-120914CAS No.: 170950-29-5Synonyms: GO-Y015TrxR1-IN-B19 (GO-Y015) is a Curcumin (HY-N0005) derivative and TrxR1 inhibitor. TrxR1-IN-B19 inhibits de novo selenoprotein synthesis, suppresses SeP and GPx expression, and impairs selenium incorporation into Sec-tRNA[Sec]. TrxR1-IN-B19 induces Nrf2 accumulation through Keap1 cysteine modification, HO-1 expression, GSH synthesis, ROS accumulation, ER stress, mitochondrial dysfunction, Apoptosis, and G2/M phase arrest. TrxR1-IN-B19 improves glucose tolerance and insulin sensitivity, lowers blood glucose, inhibits tumor growth, and reduces arsenic accumulation. TrxR1-IN-B19 can be used for research on type 2 diabetes, arsenite-induced toxicity, and gastric cancer.
-
TrxR-IN-3
0 ImagesCat. No.: HY-146307CAS No.: 2445565-58-0TrxR-IN-3 is a thioredoxin reductase (TrxR) inhibitor with an IC50 of 0.12 µM in MDA-MB-231 cells. TrxR-IN-3 inhibits TrxR enzyme activity and suppresses TrxR protein expression. TrxR-IN-3 induces reactive oxygen species (ROS) accumulation, apoptosis, and autophagy. TrxR-IN-3 modulates apoptosis-related proteins by decreasing anti-apoptotic protein levels and increasing caspase cleavage. TrxR-IN-3 modulates autophagy-related proteins by increasing autophagy markers and reducing autophagy substrate proteins. TrxR-IN-3 can be used for breast cancer research.
-
TrxR1-IN-1
0 ImagesCat. No.: HY-149390CAS No.: 3052303-04-2TrxR1-IN-1 (Compound 5j) is a TrxR1 inhibitor (IC50: 8.8 μM). TrxR1-IN-1 has anticancer activity, with IC50s of MCF-7 (1.5 μM), HeLa (1.7 μM), BGC-823 (2.4 μM), SW-480 (2.8 μM), A549 (2.1 μM). TrxR1-IN-1 has antioxidant activity, and scavenges DPPH radical.
-
Thioredoxin Reductase, E.coli
0 ImagesCat. No.: HY-P2759AThioredoxin Reductase, E. coli is a thioredoxin reductase (TrxR) derived from Escherichia coli. Thioredoxin Reductase, E. coli has been used in assays for thioredoxin reductase activity and peroxiredoxin, as well as in studies investigating the synergistic effects of broccoli sprout extract and selenium on the upregulation of thioredoxin reductase in human liver cells.
-
CS47
0 ImagesCat. No.: HY-175806CAS No.: 1372792-51-2CS47 is a Thioredoxin Reductase 1 (TRXR1) inhibitor and ferroptosis inducer. CS47 binds non-covalently to sites between the FAD and NADPH pockets of TRXR1. CS47 drives glutathione depletion, lipid reactive oxygen species accumulation, HMOX1-dependent iron overload, and selective cytotoxicity in lung cancer cells. CS47 can be used for the research of lung cancer.
-
Aurothiomalate disodium
0 ImagesCat. No.: HY-W010270ACAS No.: 74916-57-7Aurothiomalate disodium acts as an inhibitor of PKCI and TrxR1. Aurothiomalate disodium disrupts the PKCI-Par6-Rac1 signaling pathway, and also inhibits TrxR1 activity, TNFα-induced NF-κB activation, and the expression of pro-inflammatory genes. Aurothiomalate disodium blocks Kras-mediated BASC expansion and lung tumor growth, inhibits anchorage-independent growth and tumorigenicity of lung cancer cells, and suppresses neutrophil chemotaxis, phagocytosis, and leukocyte extravasation. Aurothiomalate disodium can be used in research related to rheumatoid arthritis and non-small cell lung cancer.
-
TrxR-IN-6
0 ImagesCat. No.: HY-157158CAS No.: 3032446-53-7TrxR-IN-6 is a thioredoxin reductase (TrxR) inhibitor. TrxR-IN-6 induces reactive oxygen species (ROS) accumulation and cell apoptosis. TrxR-IN-6 induces mitochondrial dysfunction, endoplasmic reticulum stress and DNA damage. TrxR-IN-6 can be used for the research of breast cancer, leukemia.
-
Topoisomerase I/II-IN-10
0 ImagesCat. No.: HY-189664Topoisomerase I/II-IN-10 is a Topoisomerase I/II inhibitor. Topoisomerase I/II-IN-10 inhibits TrxR1 activity, impairs the thioredoxin antioxidant system, and promotes oxidative stress. Topoisomerase I/II-IN-10 does not intercalate into DNA and does not induce DNA relaxation in the absence of topoisomerase. Topoisomerase I/II-IN-10 induces Apoptosis, increases the intracellular total oxidation state, and increases the Bax/Bcl-2 ratio. Topoisomerase I/II-IN-10 can be used for research on lung cancer.
-
TrxR-IN-4
0 ImagesCat. No.: HY-146350CAS No.: 2414906-32-2TrxR-IN-4 is a thioredoxin reductase (TrxR) inhibitor with a rat IC50 of 0.37 μM. TrxR-IN-4 inhibits TrxR activity, elevates reactive oxygen species (ROS) and induces apoptosis. TrxR-IN-4 mediates endoplasmic reticulum stress and induces mitochondrial dysfunction. TrxR-IN-4 can be used for the research of hepatocellular carcinoma.
-
Platinum(IV) Prodrug-1
0 ImagesCat. No.: HY-183544Platinum (IV) Prodrug-1 is a Pt (IV) prodrug and selective TrxR1 inhibitor. Platinum (IV) Prodrug-1 induces ferroptosis (Ferroptosis) by depleting glutathione, accumulating intracellular lipid peroxides, and inactivating Glutathione peroxidase 4. Platinum (IV) Prodrug-1 triggers endoplasmic reticulum stress and immunogenic cell death via excessive accumulation of intracellular ROS. Platinum (IV) Prodrug-1 exhibits anticancer activity against both Cisplatin (HY-17394)-sensitive and Cisplatin-resistant triple-negative breast cancer cells. Platinum (IV) Prodrug-1 can be used for the research of triple-negative breast cancer.
-
TrxR-IN-7
0 ImagesCat. No.: HY-172086TrxR-IN-7 is a thioredoxin reductase (TrxR) inhibitor with an IC50 of 3.5 μM. TrxR-IN-7 induces reactive oxygen species (ROS) generation and apoptosis in tumor cells. TrxR-IN-7 can be used for the research of liver cancer and breast cancer.
-
LW-216
0 ImagesCat. No.: HY-163724CAS No.: 2146090-18-6
-
CPUL1
0 ImagesCat. No.: HY-151802CAS No.: 2043660-80-4CPUL1 is a TrxR inhibitor, which shows proliferation-inhibitory and anti-metastatic activity against A549 cells. CPUL1 influences EMT (epithelial-mesenchymal transition) via inducing ROS-mediated ERK/JNK signaling by inhibiting TrxR1 enzyme activity. CPUL1 in combination with α-Lipoic Acid (HY-N0492) or Dithiodipropionic acid (HY-W014395) is more effective.
-
FEACYP
0 ImagesCat. No.: HY-161811FEACYP is a thioredoxin reductase (TrxR) inhibitor. FEACYP inhibits thioredoxin reductase activity, induces ROS by increasing basal cellular hydrogen peroxide production, suppresses tumor growth, exerts cytotoxicity against human cancer cells, and exhibits antiproliferative activity in human pancreatic cancer 3D spheroids. FEACYP can be used in the research of ovarian cancer, colon cancer, pancreatic cancer, and lung cancer.
